Unannounced Pharmaceutical Inspections
Core Inspection Disciplines
1.Quality System
Focus areas: independence of the quality unit, defined responsibilities of quality personnel, change control procedures, Corrective and Preventive Actions (CAPA), annual product quality reviews (APQR), etc.
2.Facilities & Equipment
Focus areas: design, maintenance and cleaning of critical infrastructure including HVAC systems, pharmaceutical water systems and process gas systems; cross-contamination mitigation controls.
3.Materials Management
Focus areas: supplier qualification and validation, raw material release protocols, unique material coding, controlled warehousing and storage conditions.
4.Production Operations
Focus areas: batch production records, process validation, cleaning validation, deviation handling and Out-of-Specification (OOS) investigation workflows.
5.Packaging & Labeling
Focus areas: label management controls, packaging execution, in-line inspection protocols and anti-counterfeiting measures.
6.Laboratory Controls
Focus areas: analytical method validation, Out-of-Trend (OOT) and OOS root-cause investigations, stability testing programs and retained sample management.
Data Integrity: Special Focus Area
Audit Trails: Verification of mandatory audit trail activation, regular audit trail reviews, and corresponding corrective actions triggered by anomalous trail entries.
Raw Data: Mandatory review of original electronic source data instead of aggregated summary reports.
Metadata: Completeness verification of timestamps, user identification credentials and full modification history logs.
Data Backup & Recovery: Audit of backup frequency, periodic recovery validation testing and off-site secure data storage arrangements.
Unauthorized Data Manipulation: Detection of any unapproved deletion or overwriting of source data.
On-Site Verification Practices
Quality Metrics Evaluation
Inspection Priorities Across the Product Lifecycle
Pre-Approval Inspections (PAIs)
Focus: process validation packages, analytical method validation, facility readiness, consistency between commercial manufacturing facilities and information submitted in marketing applications, full data integrity verification, and alignment between application data and original source records.
Routine Surveillance Inspections
Foreign manufacturing sites are typically inspected every 2–3 years; inspections may be expedited following consumer complaints, product recalls or safety alerts. Past inspection deficiencies will be prioritized for re-verification.
For-Cause Investigations
Triggered by consumer complaints, adverse drug events, product recalls, whistleblower reports, inconsistent application data or suspected data integrity violations.
Inspection Techniques & Methodologies
- Document Review: Comprehensive review of master documents, batch manufacturing records, equipment logbooks, validation dossiers and change control archives.
- On-Site Observations: Real-time monitoring of SOP compliance during production, personnel hygiene practices, material status labeling, equipment sanitation and environmental monitoring data.
- Personnel Interviews: Structured interview protocols targeting quality heads, production staff, QC analysts and validation specialists, together with standardized inquiry techniques.
Protocols for Addressing Physical Resistance, Threats or Assaults
The manual establishes formal procedures for inspectors encountering hostile conduct:
When facing physical resistance, verbal threats or imminent risk of assault, inspectors are instructed to disengage immediately to secure personal safety. Local law enforcement or emergency medical services shall be contacted as needed. All incidents must be documented with precise, detailed records, including verbal exchanges, actions taken by involved parties, and records of attempted or completed threats, physical altercations or unauthorized seizure of inspection materials/samples.
Precedent Case of Obstructed FDA Inspection
A severe case of deliberate obstruction and interference with official inspection occurred previously:
The pharmaceutical establishment and relevant personnel imposed aggregate fines totaling USD 638,000 (approximately RMB 4.39 million): the enterprise was penalized RMB 2.7907 million, its legal representative fined RMB 400,000, and five individual staff members faced fines of RMB 200,000 or RMB 400,000 each.
During the regulatory inquiry, the company intentionally concealed employee whereabouts and provided falsified information to mislead investigators. Despite repeated official instructions to remain on-site for cooperation, relevant personnel insisted on leaving under fabricated pretexts, halting the investigation entirely. Staff members physically blocked regulators to facilitate the departure of non-compliant employees, resulting in a regulator sustaining hand injuries from being trapped between equipment. Multiple employees were mobilized to forcibly seize the inspector’s laptop containing inspection records; regulators were restrained, pushed and shoved to obstruct official duties, and the seized laptop was subsequently removed and destroyed.
The inspection team filed an on-site police report, and local law enforcement secured surveillance footage and other evidentiary materials to support enforcement actions.
